[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
OBJECTIVE
In order to study the effect of all-trans retinoic acid (ATRA) or arsenic trioxide (As2O3) treatment on the expression of tissue factor (TF) in acute promyelocytic leukemia(APL).


METHODS
The plasma level of soluble fibrin monomer complex(SFMC) and D-dimer(D-D), and the TF level of cell lysate were measured by ELISA, the transcription of TF mRNA was assessed by RT-PCR.


RESULTS
The plasma level of SFMC and D-D, the procoagulant activity(PCA) of bone marrow blasts, the TF level of cell lysate and the transcription of TF mRNA all remarkably elevated at diagnosis, while reduced after ATRA or As2O3 therapy.


CONCLUSIONS
Both ATRA and As2O3 downregulated the expression of TF mRNA, decreased the PCA and TF levels in APL cells, inhibited coagulation activation and secondary hyperfibrinolysis, thus greatly relieved the bleeding symptom in the early stage of treatment.
Zhao
W
W
Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025.
Wang
H
H
Guo
W
W
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D005260:Female; D006490:Hemostatics / Q000378:metabolism; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D013925:Thromboplastin / Q000096:biosynthesis / Q000235:genetics; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001152:Arsenicals; D006490:Hemostatics; D010087:Oxides; D012333:RNA, Messenger; D014212:Tretinoin; D013925:Thromboplastin; D000077237:Arsenic Trioxide